Myeloid-derived suppressor cell heterogeneity and subset definition

Current Opinion in Immunology

Volumn 22, Issue 2, 2010, Pages 238-244

  Peranzoni, Elisa ^a   Zilio, Serena ^a   Marigo, Ilaria ^a   Dolcetti, Luigi ^b,c   Zanovello, Paola ^a,b   Mandruzzato, Susanna ^a,b   Bronte, Vincenzo ^b,c  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD11B ANTIGEN; GAMMA INTERFERON; GR 1 ANTIGEN; LYMPHOCYTE ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CD8+ T LYMPHOCYTE; CELL COMPOSITION; CELL DIFFERENTIATION; CELL FRACTIONATION; CELL HETEROGENEITY; CELL ISOLATION; CYTOKINE PRODUCTION; HUMAN; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; METASTASIS; MONOCYTE; NONHUMAN; POLYMORPHONUCLEAR CELL; REVIEW; STEM CELL EXPANSION; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, CD11B; ANTIGENS, DIFFERENTIATION; HEMATOPOIESIS; HUMANS; IMMUNE TOLERANCE; MICE; MYELOID CELLS; MYELOID PROGENITOR CELLS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CHEMOKINE;

EID: 77951258918     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2010.01.021     Document Type: Review

References (48)

1. Gabrilovich D.I., Bronte V., Chen S.H., Colombo M.P., Ochoa A., Ostrand-Rosenberg S., Schreiber H. The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007, 67:426. author reply 426.
2. Marigo I., Dolcetti L., Serafini P., Zanovello P., Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008, 222:162-179.
3. Sica A., Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007, 117:1155-1166.
4. Kusmartsev S., Nagaraj S., Gabrilovich D.I. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 2005, 175:4583-4592.
5. Kusmartsev S., Gabrilovich D.I. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol 2005, 174:4880-4891.
6. Sinha P., Clements V.K., Bunt S.K., Albelda S.M., Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007, 179:977-983.
7. De Palma M., Venneri M.A., Galli R., Sergi Sergi L., Politi L.S., Sampaolesi M., Naldini L. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8:211-226.
8. Pucci F., Venneri M.A., Biziato D., Nonis A., Moi D., Sica A., Di Serio C., Naldini L., De Palma M. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood 'resident' monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 2009, 114:901-914.
9. Bronte V., Cingarlini S., Marigo I., De Santo C., Gallina G., Dolcetti L., Ugel S., Peranzoni E., Mandruzzato S., Zanovello P. Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention. Immunol Invest 2006, 35:327-357.
10. Ueda Y., Kondo M., Kelsoe G. Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow. J Exp Med 2005, 201:1771-1780.
11. Gallina G., Dolcetti L., Serafini P., De Santo C., Marigo I., Colombo M.P., Basso G., Brombacher F., Borrello I., Zanovello P., et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006, 116:2777-2790.
12. Terabe M., Matsui S., Park J.M., Mamura M., Noben-Trauth N., Donaldson D.D., Chen W., Wahl S.M., Ledbetter S., Pratt B., et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003, 198:1741-1752.
13. Van Ginderachter J.A., Meerschaut S., Liu Y., Brys L., De Groeve K., Hassanzadeh Ghassabeh G., Raes G., De Baetselier P. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood 2006, 108:525-535.
14. Fleming T.J., Fleming M.L., Malek T.R. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J Immunol 1993, 151:2399-2408.
15. Nagendra S., Schlueter A.J. Absence of cross-reactivity between murine Ly-6C and Ly-6G. Cytometry A 2004, 58:195-200.
16. Sunderkotter C., Nikolic T., Dillon M.J., Van Rooijen N., Stehling M., Drevets D.A., Leenen P.J. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 2004, 172:4410-4417.
17. Jutila M.A., Kroese F.G., Jutila K.L., Stall A.M., Fiering S., Herzenberg L.A., Berg E.L., Butcher E.C. Ly-6C is a monocyte/macrophage and endothelial cell differentiation antigen regulated by interferon-gamma. Eur J Immunol 1988, 18:1819-1826.
18. Pflugh D.L., Maher S.E., Bothwell A.L. Ly-6 superfamily members Ly-6A/E. Ly-6C, and Ly-6I recognize two potential ligands expressed by B lymphocytes. J Immunol 2002, 169:5130-5136.
19. Abbitt K.B., Cotter M.J., Ridger V.C., Crossman D.C., Hellewell P.G., Norman K.E. Antibody ligation of murine Ly-6G induces neutropenia, blood flow cessation, and death via complement-dependent and independent mechanisms. J Leukoc Biol 2009, 85:55-63.
20. Ribechini E., Leenen P.J., Lutz M.B. Gr-1 antibody induces STAT signaling, macrophage marker expression and abrogation of myeloid-derived suppressor cell activity in BM cells. Eur J Immunol 2009.
21. Dolcetti L., Marigo I., Mantelli B., Peranzoni E., Zanovello P., Bronte V. Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett 2008, 267:216-225.
22. Huang B., Pan P.Y., Li Q., Sato A.I., Levy D.E., Bromberg J., Divino C.M., Chen S.H. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006, 66:1123-1131.
23. Youn J.I., Nagaraj S., Collazo M., Gabrilovich D.I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008, 181:5791-5802.
24. Dolcetti L., Peranzoni E., Ugel S., Marigo I., Fernandez Gomez A., Mesa C., Geilich M., Winkels G., Traggiai E., Casati A., et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 2009, 40:22-35.
25. Movahedi K., Guilliams M., Van den Bossche J., Van den Bergh R., Gysemans C., Beschin A., De Baetselier P., Van Ginderachter J.A. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008, 111:4233-4244.
26. Bronte V., Apolloni E., Cabrelle A., Ronca R., Serafini P., Zamboni P., Restifo N.P., Zanovello P. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000, 96:3838-3846.
27. Greifenberg V., Ribechini E., Rossner S., Lutz M.B. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur J Immunol 2009, 39:2865-2876.
28. Umemura N., Saio M., Suwa T., Kitoh Y., Bai J., Nonaka K., Ouyang G.F., Okada M., Balazs M., Adany R., et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol 2008, 83:1136-1144.
29. Markiewski M.M., DeAngelis R.A., Benencia F., Ricklin-Lichtsteiner S.K., Koutoulaki A., Gerard C., Coukos G., Lambris J.D. Modulation of the antitumor immune response by complement. Nat Immunol 2008, 9:1225-1235.
30. Fridlender Z.G., Sun J., Kim S., Kapoor V., Cheng G., Ling L., Worthen G.S., Albelda S.M. Polarization of tumor-associated neutrophil phenotype by TGF-beta: 'N1' versus 'N2' TAN. Cancer Cell 2009, 16:183-194.
31. Sawanobori Y., Ueha S., Kurachi M., Shimaoka T., Talmadge J.E., Abe J., Shono Y., Kitabatake M., Kakimi K., Mukaida N., et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008, 111:5457-5466.
32. Dietlin T.A., Hofman F.M., Lund B.T., Gilmore W., Stohlman S.A., van der Veen R.C. Mycobacteria-induced Gr-1+ subsets from distinct myeloid lineages have opposite effects on T cell expansion. J Leukoc Biol 2007, 81:1205-1212.
33. Zhu B., Bando Y., Xiao S., Yang K., Anderson A.C., Kuchroo V.K., Khoury S.J. CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol 2007, 179:5228-5237.
34. Zea A.H., Rodriguez P.C., Atkins M.B., Hernandez C., Signoretti S., Zabaleta J., McDermott D., Quiceno D., Youmans A., O'Neill A., et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005, 65:3044-3048.
35. Rodriguez P.C., Ernstoff M.S., Hernandez C., Atkins M., Zabaleta J., Sierra R., Ochoa A.C. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009, 69:1553-1560.
36. Filipazzi P., Valenti R., Huber V., Pilla L., Canese P., Iero M., Castelli C., Mariani L., Parmiani G., Rivoltini L. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007, 25:2546-2553.
37. Vuk-Pavlovic S., Bulur P.A., Lin Y., Qin R., Szumlanski C.L., Zhao X., Dietz A.B. Immunosuppressive CD14(+)HLA-DR(low/-) monocytes in prostate cancer. Prostate 2009.
38. Serafini P., Meckel K., Kelso M., Noonan K., Califano J., Koch W., Dolcetti L., Bronte V., Borrello I. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006, 203:2691-2702.
39. Hoechst B., Ormandy L.A., Ballmaier M., Lehner F., Kruger C., Manns M.P., Greten T.F., Korangy F. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008, 135:234-243.
40. Mandruzzato S., Solito S., Falisi E., Francescato S., Chiarion-Sileni V., Mocellin S., Zanon A., Rossi C.R., Nitti D., Bronte V., et al. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol 2009, 182:6562-6568.
41. Almand B., Clark J.I., Nikitina E., van Beynen J., English N.R., Knight S.C., Carbone D.P., Gabrilovich D.I. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001, 166:678-689.
42. Kusmartsev S., Su Z., Heiser A., Dannull J., Eruslanov E., Kubler H., Yancey D., Dahm P., Vieweg J. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 2008, 14:8270-8278.
43. Liu C.Y., Wang Y.M., Wang C.L., Feng P.H., Ko H.W., Liu Y.H., Wu Y.C., Chu Y., Chung F.T., Kuo C.H., et al. Population alterations of L: -arginase- and inducible nitric oxide synthase-expressed CD11b(+)/CD14 (-)/CD15 (+)/CD33 (+) myeloid-derived suppressor cells and CD8 (+) T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2009, 10.1007/s00432-009-0634-0.
44. Srivastava M.K., Bosch J.J., Thompson J.A., Ksander B.R., Edelman M.J., Ostrand-Rosenberg S. Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother 2008, 57:1493-1504.
45. Diaz-Montero C.M., Salem M.L., Nishimura M.I., Garrett-Mayer E., Cole D.J., Montero A.J. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009, 58:49-59.
46. Auffray C., Sieweke M.H., Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009, 27:669-692.
47. Bronte V. Myeloid-derived suppressor cells in inflammation: uncovering cell subsets with enhanced immunosuppressive functions. Eur J Immunol 2009, 39:2670-2672.
48. Bainton D.F. Morphology of Neutrophils and Neutrophil Precursors 1990, McGraw-Hill, New York. W.J. Williams, E. Beutler, A.J. Erslev, L. MA (Eds.).